458 related articles for article (PubMed ID: 24504937)
1. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT.
Voors AA; van Veldhuisen DJ; Robertson M; Ford I; Borer JS; Böhm M; Komajda M; Swedberg K; Tavazzi L;
Eur J Heart Fail; 2014 Apr; 16(4):426-34. PubMed ID: 24504937
[TBL] [Abstract][Full Text] [Related]
2. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial.
Böhm M; Swedberg K; Komajda M; Borer JS; Ford I; Dubost-Brama A; Lerebours G; Tavazzi L;
Lancet; 2010 Sep; 376(9744):886-94. PubMed ID: 20801495
[TBL] [Abstract][Full Text] [Related]
3. Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure.
Komajda M; Böhm M; Borer J; Ford I; Krum H; Tase A; Tavazzi L; Swedberg K
Eur J Heart Fail; 2013 Jan; 15(1):79-84. PubMed ID: 22892123
[TBL] [Abstract][Full Text] [Related]
4. Influence of Cardiovascular and Noncardiovascular Co-morbidities on Outcomes and Treatment Effect of Heart Rate Reduction With Ivabradine in Stable Heart Failure (from the SHIFT Trial).
Böhm M; Robertson M; Ford I; Borer JS; Komajda M; Kindermann I; Maack C; Lainscak M; Swedberg K; Tavazzi L
Am J Cardiol; 2015 Dec; 116(12):1890-7. PubMed ID: 26508709
[TBL] [Abstract][Full Text] [Related]
5. Ivabradine: in adults with chronic heart failure with reduced left ventricular ejection fraction.
Perry CM
Am J Cardiovasc Drugs; 2012 Dec; 12(6):415-26. PubMed ID: 23181944
[TBL] [Abstract][Full Text] [Related]
6. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.
Swedberg K; Komajda M; Böhm M; Borer JS; Ford I; Dubost-Brama A; Lerebours G; Tavazzi L;
Lancet; 2010 Sep; 376(9744):875-85. PubMed ID: 20801500
[TBL] [Abstract][Full Text] [Related]
7. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.
Swedberg K; Komajda M; Böhm M; Borer J; Robertson M; Tavazzi L; Ford I;
J Am Coll Cardiol; 2012 May; 59(22):1938-45. PubMed ID: 22617188
[TBL] [Abstract][Full Text] [Related]
8. I(f) current inhibitor ivabradine in patients with idiopathic dilated cardiomyopathy: Impact on the exercise tolerance and quality of life.
Abdel-Salam Z; Rayan M; Saleh A; Abdel-Barr MG; Hussain M; Nammas W
Cardiol J; 2015; 22(2):227-32. PubMed ID: 25179314
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy and safety analysis of ivabradine hydrochloride treatment of Chinese patients with chronic heart failure: subgroup analysis of Chinese patients in the SHIFT study].
Hu DY; Huang DJ; Yuan ZY; Zhao RP; Yan XW; Wang MH;
Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Mar; 45(3):190-197. PubMed ID: 28316174
[No Abstract] [Full Text] [Related]
10. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy.
Böhm M; Borer JS; Camm J; Ford I; Lloyd SM; Komajda M; Tavazzi L; Talajic M; Lainscak M; Reil JC; Ukena C; Swedberg K
Eur J Heart Fail; 2015 May; 17(5):518-26. PubMed ID: 25801408
[TBL] [Abstract][Full Text] [Related]
11. Impact of left bundle branch block on heart rate and its relationship to treatment with ivabradine in chronic heart failure.
Reil JC; Robertson M; Ford I; Borer J; Komajda M; Swedberg K; Tavazzi L; Böhm M
Eur J Heart Fail; 2013 Sep; 15(9):1044-52. PubMed ID: 23696612
[TBL] [Abstract][Full Text] [Related]
12. Heart rate and its reduction in chronic heart failure and beyond.
Nikolovska Vukadinović A; Vukadinović D; Borer J; Cowie M; Komajda M; Lainscak M; Swedberg K; Böhm M
Eur J Heart Fail; 2017 Oct; 19(10):1230-1241. PubMed ID: 28627045
[TBL] [Abstract][Full Text] [Related]
13. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
Fox K; Ferrari R; Tendera M; Steg PG; Ford I;
Am Heart J; 2006 Nov; 152(5):860-6. PubMed ID: 17070146
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial.
Komajda M; Tavazzi L; Francq BG; Böhm M; Borer JS; Ford I; Swedberg K;
Eur J Heart Fail; 2015 Dec; 17(12):1294-301. PubMed ID: 26377342
[TBL] [Abstract][Full Text] [Related]
15. Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT).
Swedberg K; Komajda M; Böhm M; Borer JS; Ford I; Tavazzi L
Eur J Heart Fail; 2010 Jan; 12(1):75-81. PubMed ID: 19892778
[TBL] [Abstract][Full Text] [Related]
16. Ivabradine treatment prevents dobutamine-induced increase in heart rate in patients with acute decompensated heart failure.
Cavusoglu Y; Mert U; Nadir A; Mutlu F; Morrad B; Ulus T
J Cardiovasc Med (Hagerstown); 2015 Sep; 16(9):603-9. PubMed ID: 24922198
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study).
Borer JS; Böhm M; Ford I; Robertson M; Komajda M; Tavazzi L; Swedberg K;
Am J Cardiol; 2014 Feb; 113(3):497-503. PubMed ID: 24332674
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study.
Tavazzi L; Swedberg K; Komajda M; Böhm M; Borer JS; Lainscak M; Ford I;
Eur J Heart Fail; 2013 Nov; 15(11):1296-303. PubMed ID: 23803951
[TBL] [Abstract][Full Text] [Related]
19. Effect of Visit-to-Visit Variation of Heart Rate and Systolic Blood Pressure on Outcomes in Chronic Systolic Heart Failure: Results From the Systolic Heart Failure Treatment With the If Inhibitor Ivabradine Trial (SHIFT) Trial.
Böhm M; Robertson M; Borer J; Ford I; Komajda M; Mahfoud F; Ewen S; Swedberg K; Tavazzi L
J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26873681
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT.
Komajda M; Böhm M; Borer JS; Ford I; Robertson M; Manolis AJ; Tavazzi L; Swedberg K;
Eur J Heart Fail; 2014 Jul; 16(7):810-6. PubMed ID: 24961493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]